国务院发布《决定》,加快网上药店增开进程

2017-02-05 常有才 国务院发布《决定》,加快网上药店增开进程

近日,国务院发布相关《决定》取消了“互联网药品交易服务资格B证、C证的审批”,这,是否暗示着要加快网上药店的增开进程呢?

很多药房与药店都想在电商市场分到一块肥肉,但由于《互联网药品交易资格证》门槛太高、要求太多他们不得望尘莫及,不过寒冬一过,春天已临,这些怀揣着“网上药店”的实体药房药店,将在2017年遇暖如愿。因为,国务院发布相关《决定》取消了“互联网药品交易服务资格B证、C证的审批”,这,是否暗示着要加快网上药店的增开进程呢?信号明确:国务院发文取消B证、C证审批据了解,互联网药品交易服务资格证书共有三种,分别是A证、B证、C证。A证为国家局审批,是第三方交易服务平台;而B证和C证都均由地方局审批,不同的是,B证是获证单位与其他企业进行药品交易,C证则是获证单位向个人消费者提供药品交易服务。从国务院的发文内容中不难看出,这次取消的审批项目主要是指B证与C证。因为据据《中国政府网》公开的信息显示,经李克强总理签批,国务院日前印发《关于第三批取消中央指定地方实施行政许可事项的决定》(以下简称《决定》)。该《决定》明确提出,“取消互联网药品交易服务企业(第三方平台A证除外)审批”。暗语隐藏:加速网上药店增开速度?有报道称,美国的第一家网上药店出现在1999年,但到了2000年仅一年时间就增开了1000家,

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1926659, encodeId=d5421926659f0, content=<a href='/topic/show?id=c312e943903' target=_blank style='color:#2F92EE;'>#网上药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79439, encryptionId=c312e943903, topicName=网上药店)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 16 22:54:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635042, encodeId=fe6916350425f, content=<a href='/topic/show?id=a262200e41b' target=_blank style='color:#2F92EE;'>#上药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20074, encryptionId=a262200e41b, topicName=上药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b4d22392413, createdName=12498623m100暂无昵称, createdTime=Sat Mar 18 06:54:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345863, encodeId=3c52134586355, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 07 00:54:00 CST 2017, time=2017-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174397, encodeId=70fe1e43976e, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Feb 05 20:00:30 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174356, encodeId=67941e435637, content=拭目以待拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Sun Feb 05 10:44:29 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174354, encodeId=72a21e43542d, content=冲出体制, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:27 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174353, encodeId=89711e4353c9, content=完善自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:12 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174352, encodeId=096d1e435231, content=拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:03 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174351, encodeId=c40d1e4351c4, content=优良竞争, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:50 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174350, encodeId=5edf1e43501f, content=加速发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:36 CST 2017, time=2017-02-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1926659, encodeId=d5421926659f0, content=<a href='/topic/show?id=c312e943903' target=_blank style='color:#2F92EE;'>#网上药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79439, encryptionId=c312e943903, topicName=网上药店)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 16 22:54:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635042, encodeId=fe6916350425f, content=<a href='/topic/show?id=a262200e41b' target=_blank style='color:#2F92EE;'>#上药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20074, encryptionId=a262200e41b, topicName=上药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b4d22392413, createdName=12498623m100暂无昵称, createdTime=Sat Mar 18 06:54:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345863, encodeId=3c52134586355, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 07 00:54:00 CST 2017, time=2017-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174397, encodeId=70fe1e43976e, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Feb 05 20:00:30 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174356, encodeId=67941e435637, content=拭目以待拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Sun Feb 05 10:44:29 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174354, encodeId=72a21e43542d, content=冲出体制, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:27 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174353, encodeId=89711e4353c9, content=完善自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:12 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174352, encodeId=096d1e435231, content=拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:03 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174351, encodeId=c40d1e4351c4, content=优良竞争, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:50 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174350, encodeId=5edf1e43501f, content=加速发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:36 CST 2017, time=2017-02-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1926659, encodeId=d5421926659f0, content=<a href='/topic/show?id=c312e943903' target=_blank style='color:#2F92EE;'>#网上药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79439, encryptionId=c312e943903, topicName=网上药店)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 16 22:54:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635042, encodeId=fe6916350425f, content=<a href='/topic/show?id=a262200e41b' target=_blank style='color:#2F92EE;'>#上药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20074, encryptionId=a262200e41b, topicName=上药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b4d22392413, createdName=12498623m100暂无昵称, createdTime=Sat Mar 18 06:54:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345863, encodeId=3c52134586355, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 07 00:54:00 CST 2017, time=2017-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174397, encodeId=70fe1e43976e, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Feb 05 20:00:30 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174356, encodeId=67941e435637, content=拭目以待拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Sun Feb 05 10:44:29 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174354, encodeId=72a21e43542d, content=冲出体制, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:27 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174353, encodeId=89711e4353c9, content=完善自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:12 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174352, encodeId=096d1e435231, content=拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:03 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174351, encodeId=c40d1e4351c4, content=优良竞争, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:50 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174350, encodeId=5edf1e43501f, content=加速发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:36 CST 2017, time=2017-02-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1926659, encodeId=d5421926659f0, content=<a href='/topic/show?id=c312e943903' target=_blank style='color:#2F92EE;'>#网上药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79439, encryptionId=c312e943903, topicName=网上药店)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 16 22:54:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635042, encodeId=fe6916350425f, content=<a href='/topic/show?id=a262200e41b' target=_blank style='color:#2F92EE;'>#上药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20074, encryptionId=a262200e41b, topicName=上药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b4d22392413, createdName=12498623m100暂无昵称, createdTime=Sat Mar 18 06:54:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345863, encodeId=3c52134586355, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 07 00:54:00 CST 2017, time=2017-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174397, encodeId=70fe1e43976e, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Feb 05 20:00:30 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174356, encodeId=67941e435637, content=拭目以待拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Sun Feb 05 10:44:29 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174354, encodeId=72a21e43542d, content=冲出体制, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:27 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174353, encodeId=89711e4353c9, content=完善自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:12 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174352, encodeId=096d1e435231, content=拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:03 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174351, encodeId=c40d1e4351c4, content=优良竞争, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:50 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174350, encodeId=5edf1e43501f, content=加速发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:36 CST 2017, time=2017-02-05, status=1, ipAttribution=)]
    2017-02-05 1dd8c52fm63(暂无匿称)

    了解了解!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1926659, encodeId=d5421926659f0, content=<a href='/topic/show?id=c312e943903' target=_blank style='color:#2F92EE;'>#网上药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79439, encryptionId=c312e943903, topicName=网上药店)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 16 22:54:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635042, encodeId=fe6916350425f, content=<a href='/topic/show?id=a262200e41b' target=_blank style='color:#2F92EE;'>#上药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20074, encryptionId=a262200e41b, topicName=上药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b4d22392413, createdName=12498623m100暂无昵称, createdTime=Sat Mar 18 06:54:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345863, encodeId=3c52134586355, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 07 00:54:00 CST 2017, time=2017-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174397, encodeId=70fe1e43976e, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Feb 05 20:00:30 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174356, encodeId=67941e435637, content=拭目以待拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Sun Feb 05 10:44:29 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174354, encodeId=72a21e43542d, content=冲出体制, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:27 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174353, encodeId=89711e4353c9, content=完善自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:12 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174352, encodeId=096d1e435231, content=拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:03 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174351, encodeId=c40d1e4351c4, content=优良竞争, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:50 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174350, encodeId=5edf1e43501f, content=加速发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:36 CST 2017, time=2017-02-05, status=1, ipAttribution=)]
    2017-02-05 Jackie Li

    拭目以待拭目以待

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1926659, encodeId=d5421926659f0, content=<a href='/topic/show?id=c312e943903' target=_blank style='color:#2F92EE;'>#网上药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79439, encryptionId=c312e943903, topicName=网上药店)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 16 22:54:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635042, encodeId=fe6916350425f, content=<a href='/topic/show?id=a262200e41b' target=_blank style='color:#2F92EE;'>#上药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20074, encryptionId=a262200e41b, topicName=上药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b4d22392413, createdName=12498623m100暂无昵称, createdTime=Sat Mar 18 06:54:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345863, encodeId=3c52134586355, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 07 00:54:00 CST 2017, time=2017-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174397, encodeId=70fe1e43976e, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Feb 05 20:00:30 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174356, encodeId=67941e435637, content=拭目以待拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Sun Feb 05 10:44:29 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174354, encodeId=72a21e43542d, content=冲出体制, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:27 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174353, encodeId=89711e4353c9, content=完善自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:12 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174352, encodeId=096d1e435231, content=拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:03 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174351, encodeId=c40d1e4351c4, content=优良竞争, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:50 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174350, encodeId=5edf1e43501f, content=加速发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:36 CST 2017, time=2017-02-05, status=1, ipAttribution=)]
    2017-02-05 yafeiliutjh

    冲出体制

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1926659, encodeId=d5421926659f0, content=<a href='/topic/show?id=c312e943903' target=_blank style='color:#2F92EE;'>#网上药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79439, encryptionId=c312e943903, topicName=网上药店)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 16 22:54:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635042, encodeId=fe6916350425f, content=<a href='/topic/show?id=a262200e41b' target=_blank style='color:#2F92EE;'>#上药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20074, encryptionId=a262200e41b, topicName=上药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b4d22392413, createdName=12498623m100暂无昵称, createdTime=Sat Mar 18 06:54:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345863, encodeId=3c52134586355, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 07 00:54:00 CST 2017, time=2017-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174397, encodeId=70fe1e43976e, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Feb 05 20:00:30 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174356, encodeId=67941e435637, content=拭目以待拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Sun Feb 05 10:44:29 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174354, encodeId=72a21e43542d, content=冲出体制, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:27 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174353, encodeId=89711e4353c9, content=完善自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:12 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174352, encodeId=096d1e435231, content=拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:03 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174351, encodeId=c40d1e4351c4, content=优良竞争, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:50 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174350, encodeId=5edf1e43501f, content=加速发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:36 CST 2017, time=2017-02-05, status=1, ipAttribution=)]
    2017-02-05 yafeiliutjh

    完善自己

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1926659, encodeId=d5421926659f0, content=<a href='/topic/show?id=c312e943903' target=_blank style='color:#2F92EE;'>#网上药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79439, encryptionId=c312e943903, topicName=网上药店)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 16 22:54:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635042, encodeId=fe6916350425f, content=<a href='/topic/show?id=a262200e41b' target=_blank style='color:#2F92EE;'>#上药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20074, encryptionId=a262200e41b, topicName=上药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b4d22392413, createdName=12498623m100暂无昵称, createdTime=Sat Mar 18 06:54:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345863, encodeId=3c52134586355, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 07 00:54:00 CST 2017, time=2017-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174397, encodeId=70fe1e43976e, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Feb 05 20:00:30 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174356, encodeId=67941e435637, content=拭目以待拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Sun Feb 05 10:44:29 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174354, encodeId=72a21e43542d, content=冲出体制, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:27 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174353, encodeId=89711e4353c9, content=完善自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:12 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174352, encodeId=096d1e435231, content=拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:03 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174351, encodeId=c40d1e4351c4, content=优良竞争, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:50 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174350, encodeId=5edf1e43501f, content=加速发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:36 CST 2017, time=2017-02-05, status=1, ipAttribution=)]
    2017-02-05 yafeiliutjh

    拭目以待

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1926659, encodeId=d5421926659f0, content=<a href='/topic/show?id=c312e943903' target=_blank style='color:#2F92EE;'>#网上药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79439, encryptionId=c312e943903, topicName=网上药店)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 16 22:54:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635042, encodeId=fe6916350425f, content=<a href='/topic/show?id=a262200e41b' target=_blank style='color:#2F92EE;'>#上药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20074, encryptionId=a262200e41b, topicName=上药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b4d22392413, createdName=12498623m100暂无昵称, createdTime=Sat Mar 18 06:54:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345863, encodeId=3c52134586355, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 07 00:54:00 CST 2017, time=2017-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174397, encodeId=70fe1e43976e, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Feb 05 20:00:30 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174356, encodeId=67941e435637, content=拭目以待拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Sun Feb 05 10:44:29 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174354, encodeId=72a21e43542d, content=冲出体制, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:27 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174353, encodeId=89711e4353c9, content=完善自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:12 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174352, encodeId=096d1e435231, content=拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:03 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174351, encodeId=c40d1e4351c4, content=优良竞争, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:50 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174350, encodeId=5edf1e43501f, content=加速发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:36 CST 2017, time=2017-02-05, status=1, ipAttribution=)]
    2017-02-05 yafeiliutjh

    优良竞争

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1926659, encodeId=d5421926659f0, content=<a href='/topic/show?id=c312e943903' target=_blank style='color:#2F92EE;'>#网上药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79439, encryptionId=c312e943903, topicName=网上药店)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 16 22:54:00 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635042, encodeId=fe6916350425f, content=<a href='/topic/show?id=a262200e41b' target=_blank style='color:#2F92EE;'>#上药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20074, encryptionId=a262200e41b, topicName=上药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b4d22392413, createdName=12498623m100暂无昵称, createdTime=Sat Mar 18 06:54:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345863, encodeId=3c52134586355, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Feb 07 00:54:00 CST 2017, time=2017-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174397, encodeId=70fe1e43976e, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Feb 05 20:00:30 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174356, encodeId=67941e435637, content=拭目以待拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Sun Feb 05 10:44:29 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174354, encodeId=72a21e43542d, content=冲出体制, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:27 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174353, encodeId=89711e4353c9, content=完善自己, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:12 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174352, encodeId=096d1e435231, content=拭目以待, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:32:03 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174351, encodeId=c40d1e4351c4, content=优良竞争, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:50 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174350, encodeId=5edf1e43501f, content=加速发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sun Feb 05 10:31:36 CST 2017, time=2017-02-05, status=1, ipAttribution=)]
    2017-02-05 yafeiliutjh

    加速发展

    0

相关资讯

知情人曝料:山东如意新特大药房将上市新三板

近日,有知情人士向笔者曝料,山东如意新特大药房有限公司执行董事兼总经理孙镇在做2016年的年终总结时透露“将上市新三板,上市辅导工作已经启动”..

前列腺癌不易被发现,科普不到位是短板

近年来,前列腺癌成了严重威胁男性健康的“杀手”,而医学科普知识方面的普及与推广是最大短板

构建疾病、健康、养生整体解决方案的思路

为消费者提供的疾病、健康、养生整体解决方案,要从营销层面提升到战略层面,系统地进行规划才能发挥最大作用。

制药企业新营销怎么干才能成功?

未来5年,医药市场经营结构将会发生大的变化,国家针对医药商业结构的颠覆性治理和对医药经营秩序的沉重打击,会让很多制药企业原有的营销组织竞争效率快速下降。

鼎臣咨询:我国药企管控面临的主要问题

现在医药行业很多集团型药企给予各分公司、子公司很大的经营管理自主权

鼎臣咨询:药品营销方案容易进入的误区

很多药企制订营销整体解决方案会进入一个误区,就是总想把自己的企业介绍、自己的产品尽可能的放大,或者多篇幅进行宣传,这种做法非常不可用。